Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to helping patients live better. Blue Note is merging deep scientific and clinical expertise with digital and gaming ideas to transform care for seriously ill patients. Working closely with leading medical researchers and patient advocacy organizations, Blue Note is creating clinically validated, FDA-approvable, and prescription-only digital devices to treat the burden of illness. The company was founded in 2018 and is based in San Francisco, California.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solutions provide people everywhere with connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, life science companies and patients alike, Biofourmis’ connected platform improves patient outcomes, accelerates drug development, and closes critical gaps in care—ultimately making science smarter, healthcare simpler, and patients healthier.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solutions provide people everywhere with connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, life science companies and patients alike, Biofourmis’ connected platform improves patient outcomes, accelerates drug development, and closes critical gaps in care—ultimately making science smarter, healthcare simpler, and patients healthier.

Cancer-related distress, which can be defined as any unpleasant feeling, emotion, or experience that affects a cancer patient’s quality of life or ability to cope with cancer diagnosis and treatment, affects millions of people. Fewer than half of those who experience cancer-related distress have access to the mental health care they need to find relief. Blue Note Therapeutics is working to close this gap.